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Received August 14, 2015; accepted October 22, 2015AbstractBackground: Several changes in physiological characteristics occur during long-distance and 24-hour ultramarathons, including hyponatremia,
skeletal muscle breakdown, plasma volume changes, iron depletion, anemia, and possible hepatic damage. The purpose of this study was to
investigate the impact of hepatitis B virus (HBV) carrier status on liver function during multi-day races.
Methods: This prospective study recruited 10 Taiwanese runners who were scheduled to participate in the 7-day 2008 Athens Ultramarathon
Festival Race, and three of them were chronic carriers of HBV. Blood samples were collected before, during, and 3 days after the race, including
alkaline phosphatase (ALP), albumin (ALB), total protein (TP) levels, alanine aminotransferase (ALT), aspartate aminotransferase (AST), and
total bilirubin (T-BIL)
Results: Ten Taiwanese runners (40% female; average age 52.3 ± 7.9 years) who all planned to run in the race were recruited. Three runners
were chronic carriers of HBV (HBV carrier), and all participants were anti-HCV antibody-negative and anti-hepatitis A virus (HAV) IgG-
positive. There were no significant time-by-group effects on ALP, ALB, and TP levels, but the change over time effects were significant
( p < 0.001, p ¼ 0.001 and p ¼ 0.010, respectively). ALT, AST, and T-BIL increased significantly to markedly higher levels in the HBV carrier
group compared to the non-carrier group (group effect p ¼ 0.009, p ¼ 0.004, and p ¼ 0.05, respectively), and the time-by-group interaction was
also significant for these liver function markers ( p < 0.001, p < 0.001, and p ¼ 0.001, respectively).
Conclusion: Compared to their counterparts, runners who are HBV carriers had significantly greater increases in levels of ALT, AST, and T-BIL
during a 7-day ultramarathon, indicating that the liver function of carriers is more highly impacted in these races.
Copyright © 2016, the Chinese Medical Association. Published by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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In recent decades, ultramarathons have become increas-
ingly popular. An ultramarathon is a sporting event where
participants run distances longer than the traditional marathon
length of 42.195 km (26 miles), according to the official
definition of marathon originating from ancient Greece.1
There are two general types of events: (1) those covering asevier Taiwan LLC. This is an open access article under the CC BY-NC-ND
180 S.-L. Chou et al. / Journal of the Chinese Medical Association 79 (2016) 179e184specified distance; and (2) those covering a specified period of
time. In recent years, an increasing number of athletes have
been participating in multiday races, such as 6- or 7-day
ultramarathons. In such races, athletes can independently
allocate their time spent resting and racing during each day. In
preparation for the race, most participants schedule and un-
dergo a moderate-intensity ultra-endurance running exercise,
which includes hours of scheduled rest every day. As a gauge
of their overall race capacity and performance, many partici-
pants view recovering physiological stability to be more
important than maintaining explosive force.
Numerous reports have been published on changes in
physiological characteristics that occur during long-distance
and 24-hr ultramarathons,2e8 including hyponatremia, skel-
etal muscle breakdown, plasma volume changes, iron deple-
tion, anemia, and possible hepatic damage. It has been
established that physical exercise results in elevated liver
function tests for enzymes such as lactate dehydrogenase
(LDH), alanine aminotransferase (ALT), aspartate amino-
transferase (AST), total bilirubin (T-BIL), and alkaline phos-
phatase (ALP).9e11 These results indicate that liver cell
damage does occur in runners, and additionally that reduced
albumin (ALB) levels reflect damage to the proper anabolic
functioning of hepatic cells. The liver damage observed in
these runners is directly proportional to the workload experi-
enced.2 However, to the best of our knowledge, there have
been no previous studies investigating liver function in runners
participating in 7-day ultramarathons.
Hepatitis B virus (HBV) infection is one of the most
common infectious diseases in the world. An estimated 240
million people are chronically infected with the disease,12 as
manifested by persistence of the virus and HBV surface an-
tigen (HBsAg) in serum, and production of viral antigens and
HBV DNA in the liver. HBV attacks the liver, causing acute
and chronic disease; more than one million individuals die
annually of HBV-related chronic liver disease.13 Taiwan is a
hyperendemic area for liver disease, where the seroprevalence
of HBV and HCV is estimated to be 17.3% and 4.4%,
respectively.14,15
In Taiwan, the first 100-km ultramarathon was held in
1998, and a 24-hour ultramarathon has taken place annually
since 1999. Because increasing numbers of runners participate
in such events each year, understanding changes in the ath-
letes' physiological conditions has become increasingly
important; however, the impact of being a chronic HBV carrier
in such circumstances remains unclear.
The first objective of our study was to determine the
changes in runners' liver function as demonstrated by tests on
consecutive days of a 7-day ultramarathon, while the sec-
ondary objective was to explore the impact under those con-
ditions of being a chronic carrier of HBV.
2. Methods
All Taiwanese entrants into the 7-day 2008 Athens Ultra-
marathon Festival Race were invited to participate in the study.
For those who chose to enroll, all participants completed pre-race (Day 0), in-race (Days 1e7), and post-race (Days 8 and
10) examinations, as follows: (1) pre-race (Day 0): height and
weight were recorded, and blood samples were collected in the
afternoon for basic measurements by the medical team. Par-
ticipants signed a consent form and filled out a health ques-
tionnaire; (2) in-race (Days 1e7): blood samples were
collected in the mornings of all 7 days of the race. Running
distances were recorded each day, as was any physical
discomfort noted by the athletes. The clinical experience of
each athlete guided administration of any necessary medica-
tion, and the athletes' regular medications were assessed by the
medical team for the possibility of causing liver damage; (3)
post-race (Days 8 and 10): blood samples were taken on these
2 days of the 3-day rest period following the competition. Day
10 samples were also used for checking hepatitis markers,
including HBsAg, HBV surface antibody (HBsAb), anti-HCV
antibody, and IgG antibody to hepatitis A virus (anti-HAV
IgG).
Venous blood samples were collected from the athletes by
vein puncture. Four vacutainer tubes were centrifuged at
1500g for 10 minutes, and then plasma was dispensed into
Eppendorf tubes (1.5 mL capacity) and immediately stored at
80ºC for future analysis. The Piccolo Comprehensive
Metabolic Panel was used for analysis of ALB, total protein
(TP), ALP, AST, ALT, and T-BIL. This study was approved by
the Ethics Committee of the Institutional Review Board of
Taipei Veterans General Hospital, VAC, and was furthermore
conducted according to international ethical standards as
described by Harriss and Atkinson.162.1. Statistical analysisMeans and standard deviations were calculated for blood
test results. Due to the small number of cases involved, we
used the Mann-Whitney U test for numerical data to evaluate
the association between HBV carrier and non-HBV carrier
runners. The numerical data of serum enzymes of daily and
post-race were compared to the values of pre-race, respec-
tively, using the Wilcoxon Signed-Rank test. Effects were
tested using general linear models that take into consideration
the fact that repeated measurements were made. Commercially
available statistical software (SPSS version 18.0, SPSS Inc,
Chicago, IL, USA) was used for statistical analysis. All sta-
tistical analyses were 2-sided, and p values < 0.05 were
considered statistically significant.
3. Results
Of the 11 Taiwanese runners participating in the race, 10
agreed to join our study. Among them, four (40%) were fe-
male, the average age was 52.3 ± 7.9 years, average height
was 163.3 ± 5.1 cm, average weight was 54.6 ± 6.2 kg, mean
marathon training duration was 11.0 ± 6.2 years, and mean
accumulated running distance during the race was
553 ± 101 km. The demographic data of the ultra-runners are
shown in Table 1. All participants denied any history of dia-
betes, hypertension, and renal disease. Three runners were
Table 1
Demographic characteristics of hepatitis B virus (HBV) carrier and non-HBV carrier runners in the 7-day ultramarathon race.
Mean ± SD (Range) HBV carrier vs
non-HBV carrier p
Total participants
n ¼ 10
HBV carrier
n ¼ 3
Non-HBV carrier
n ¼ 7
Parameter
Age (y) 52.3 ± 7.9 (41e62) 52.0 ± 8.9 (45e62) 52.4 ± 8.3 (41e62) 1.000
Weight (kg) 54.6 ± 6.2 (41.0e62.0) 55.3 ± 4.0 (51.0e59.0) 54.2 ± 7.3 (41.0e62.0) 1.000
Height (m) 1.63 ± 0.05 (1.53e1.70) 1.64 ± 0.06 (1.58e1.69) 1.62 ± 0.05 (1.53e1.70) 0.729
BMI (kg/m2) 20.5 ± 1.7 (17.5e22.5) 20.6 ± 1.9 (18.7e22.4) 20.5 ± 1.8 (17.5e22.5) 0.909
Years of running marathon 11.0 ± 6.2 (5e21) 10.3 ± 6.8 (5e18) 11.3 ± 6.5 (5e21) 0.538
Training distance (km/wk) 0.192
> 100 km/wk 6 (100%) 1 (17%) 5 (83%)
60e100 km/wk 3 (100%) 1 (33%) 2 (67%)
40e60 km/wk 1 (100%) 1 (100%) 0
Best marathon time (min) 211.7 ± 21.2 (191e248) 202.0 ± 8.7 (192e208) 215.9 ± 21.2 (191e248) 0.425
Best 100 km UM time (min) 651 ± 80 (558e820) 618.7 ± 27.2 (588e640) 664.3 ± 92.8(558e820) 0.425
This UM score (km) 553 ± 101 (410e785) 537 ± 41 (501e582) 561 ± 121 (410e785) 0.833
Baseline liver function
ALT (U/L) 29.7 ± 11.0 33.3 ± 5.7 28.1 ± 12.7 0.183
AST (U/L) 34.7 ± 8.6 39.7 ± 8.5 32.6 ± 8.3 0.383
ALP (U/L) 8.9 ± 3.8 9.0 ± 4.3 8.9 ± 3.9 1.000
GGT (U/L) 25.7 ± 14.4 34.5 ± 29.0 23.1 ± 10.2 1.000
T-BIL (mg/dL) 0.73 ± 0.16 0.73 ± 1.53 0.73 ± 0.18 0.833
ALB 3.75 ± 0.21 3.73 ± 0.32 3.76 ± 0.18 0.833
TP 7.05 ± 0.46 7.17 ± 0.42 7.00 ± 0.49 0.517
CK (U/L) 96.8 ± 43.2 135.0 ± 9.9 85.9 ± 43.0 0.143
ALP ¼ alkaline phosphatase; ALT ¼ alanine aminotransferase; AST ¼ aspartate aminotransferase; BMI ¼ body mass index; CK ¼ creatine kinase; GGT ¼ g-
glutamyltransferase; HBV ¼ hepatitis B virus; HBV carrier ¼ hepatitis B virus carrier; SD ¼ standard deviation; T-BIL ¼ total bilirubin; UM ¼ ultramarathon;
TP ¼ total protein.
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HBsAb) and one of them was female. All of the participants
were anti-HCV antibody-negative and anti-HAV IgG-positive.
All the HBV carriers denied any history of admission for acute
hepatitis events within 5 years.
Table 2 shows the primary outcomes after general linear
model analysis for ALP, ALT, AST, T-BIL, ALB, and TP
levels. There were no significant time-by-group effects for
ALP, ALB, and TP, but the change-over-time effects were
significant ( p < 0.001, p ¼ 0.001, and p ¼ 0.010, respec-
tively). ALT, AST, and T-BIL increased significantly to
markedly higher levels in the HBV carrier group compared to
the non-HBV carrier group (group effect p ¼ 0.009, p ¼ 0.004
and p ¼ 0.05, respectively), and the time-by-group interaction
was also significant for these liver function markers
( p < 0.001, p < 0.001, and p ¼ 0.001, respectively).
Fig. 1 shows the ALT results. Levels were higher in the
HBV carrier group (group effect p ¼ 0.009), increasing from
33.3 ± 5.7 U/L at baseline to 235.3 ± 112.4 U/L on Day 7, and
then decreasing to 144.7 ± 72.3 U/L on Day 10; whereas those
in the non-HBV carrier group increased from 28.1 ± 12.7 U/L
at baseline to 84.9 ± 61.9 U/L on Day 5, and then decreased to
48.6 ± 25.4 U/L on Day 10; the time-by-group interaction was
significant ( p < 0.001).
Fig. 2 shows the AST results. Levels were higher in the
HBV carrier group (group effect p ¼ 0.004), increasing from
39.7 ± 8.5 U/L at baseline to 263.7 ± 98.9 U/L on Day 3, and
then decreasing to 86.3 ± 39.6 U/L on Day 10; while those inthe non-HBV carrier group increased from 32.6 ± 8.3 U/L at
baseline to 92.1 ± 62.5 U/L on Day 5, and then decreased to
41.4 ± 9.3 U/L on Day 10; the time-by-group interaction was
significant ( p < 0.001).
Fig. 3 shows the T-BIL results. Levels were higher in the
HBV carrier group (group effect p ¼ 0.05), increasing from
0.7 ± 0.2 mg/dL at baseline to 1.8 ± 0.4 on Day 3, and then
decreasing to 0.7 ± 0.2 mg/dL on Day 10; while those in the
non-HBV carrier group increased from 0.7 ± 0.2 mg/dL at
baseline to 1.1 ± 0.2 mg/dL on Day 2, and then decreased to
0.7 ± 0.1 mg/dL on Day 10; the time-by-group interaction was
significant ( p ¼ 0.001).
4. Discussion
Ultramarathons are becoming increasingly popular glob-
ally; there were 256 official races in 2000, rapidly escalating to
604 races per year by 2014.17 Therefore, determining athletes'
physiological changes during these events has become
increasingly important. Our study revealed clear changes in
liver enzyme levels during the course of a 7-day ultramara-
thon, for HBV carriers and non-HBV carriers alike.
There were significant differences between HBV carriers
and non-HBV carriers regarding AST and ALT changes. Our
results indicate that the chronic carrier state leads to more
extensive liver cell damage. Progression to hepatic fibrosis is
commonly found in patients with chronic HBV infections, and
up to 40% will develop cirrhosis and hepatocellular
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Table 2
Data of liver function between HBV carrier and non-HBV carrier runners along the 7-day ultra-marathon race.
HBV Measured time point Effects
Pre-Race In-Race Post-Race
Day 0 Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 Day 8 Day 10 Time Group T  G
ALP (U/L) () 8.9 ± 3.9 63.4 ± 15.6 64.1 ± 11.2 65.6 ± 11.8 65.9 ± 13.2 72.4 ± 18.3 72.4 ± 21.4 78.9 ± 21.1 71.6 ± 18.3 69 ± 18.9 < 0.001 0.176 0.090
(þ) 9 ± 4.4 87.3 ± 23.4 76.7 ± 22.6 77.3 ± 18.1 73 ± 13 74.3 ± 6.1 91.7 ± 31.6 103.3 ± 42.1 87.7 ± 24 107.3 ± 45.4
ALT (U/L) () 28.1 ± 12.7 29.7 ± 8 39.7 ± 13.1 49.7 ± 32.7 56.9 ± 34.6 84.9 ± 61.9 78.3 ± 56.4 70.4 ± 43.1 56.3 ± 32.7 48.6 ± 25.4 < 0.001 0.009 < 0.001
(þ) 33.3 ± 5.7 80.3 ± 40.1 127 ± 61.8 157 ± 78.5 176.7 ± 94.1 193.3 ± 112.4 224.7 ± 126.8 235.3 ± 112.4 213 ± 98.9 144.7 ± 72.3
AST (U/L) () 32.6 ± 8.3 47 ± 9.5 67.7 ± 42.7 75.3 ± 56 72 ± 42.3 92.1 ± 62.5 77.6 ± 48.9 65.4 ± 26.3 49.4 ± 14.2 41.4 ± 9.3 < 0.001 0.004 < 0.001
(þ) 39.7 ± 8.5 148.3 ± 60.1 261.3 ± 97.2 263.7 ± 98.9 235 ± 98.2 222.7 ± 114.7 231 ± 131.7 236 ± 109.2 186 ± 96.7 86.3 ± 39.6
T-BIL (mg/dL) () 0.7 ± 0.2 1 ± 0.2 1.1 ± 0.2 1 ± 0.3 1.1 ± 0.3 1 ± 0.4 0.9 ± 0.3 0.8 ± 0.2 0.9 ± 0.2 0.7 ± 0.1 < 0.001 0.050 0.001
(þ) 0.7 ± 0.2 1.4 ± 0.3 1.8 ± 0.4 1.8 ± 0.4 1.6 ± 0.6 1.5 ± 0.3 1.4 ± 0.9 1.5 ± 1 1 ± 0.2 0.7 ± 0.2
ALB (mg/dL) () 3.8 ± 0.2 4.2 ± 0.5 3.9 ± 0.3 3.9 ± 0.3 4.1 ± 0.4 3.8 ± 0.2 3.8 ± 0.1 3.9 ± 0.3 3.6 ± 0.2 3.8 ± 0.2 0.001 0.326 0.678
(þ) 3.7 ± 0.3 4.1 ± 0.3 4.1 ± 0.4 4 ± 0.3 3.9 ± 0.3 3.7 ± 0.2 3.8 ± 0.2 3.8 ± 0.1 3.4 ± 0.2 3.5 ± 0.1
TP (mg/dL) () 7 ± 0.5 7.1 ± 0.4 6.9 ± 0.3 6.9 ± 0.4 6.8 ± 0.5 6.7 ± 0.4 6.8 ± 0.3 7.2 ± 0.7 6.9 ± 0.6 7.1 ± 0.5 0.010 0.869 0.127
(þ) 7.2 ± 0.4 7.5 ± 0.6 7.1 ± 0.8 7 ± 0.6 6.8 ± 0.4 6.6 ± 0.3 6.7 ± 0.4 6.8 ± 0.5 6.4 ± 0.8 6.7 ± 0.5
Data presented with mean ± standard deviation. Data of Day 0 was measured before 7-day ultramarathon race and Day 8 was measured after race.
ALB ¼ albumin; ALP ¼ alkaline phosphatase; ALT ¼ alanine aminotransferase; AST ¼ aspartate aminotransferase; HBV ¼ hepatitis B virus; HBV carrier ¼ hepatitis B virus carrier; T-BIL ¼ total bilirubin;
TP ¼ total protein.
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Fig. 3. Differences in total bilirubin between HBV carrier and non-HBV carrier runners in a 7-day ultra-marathon race. HBV ¼ hepatitis B virus; HBV(þ) ¼ HBV
carriers; HBV() ¼ non-HBV carriers; T. Bil ¼ total bilirubin.
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and non-HBV carriers; and both groups normalized within the
3-day post-race rest period, implying that the changes could be
attributed to both hemolysis and hepatic damage. Further
studies are needed to evaluate the association of the degree of
hepatic fibrosis and the extent of elevated T-BIL in chronic
HBV carriers.
ALP increased significantly during the course of the ul-
tramarathon, a result consistent with previous studies. Kaplan
et al suggested that this effect is due to liver injury. However,
ALP is found in many parts of the body, including liver, bone,
and intestines, and its precise function is not yet known.21
Fallon et al2 thought that ischemic damage to the gut is a
less likely explanation for increased ALP levels, because there
is adequate hydration during races. However, significant bone
stress does occur in these athletes. Except for the liver, bone
was thought to be the most likely source of ALP, indicating
high bone turnover. In our study, ALP increased during pro-
longed running, but there was no significant difference be-
tween HBV carrier and non-HBV carrier groups, suggesting
that hepatic cell damage was not the only contributing factor.
Future studies should be designed to detect levels of the
various ALP isoenzymes in order to determine major sources
of the increase observed.
Although a recent study by Chiu et al22 showed no sig-
nificant differences between HBV carrier and non-HBV car-
rier in ALT, AST, and T-BIL of 100-km ultra-runners. For
more vigorous exercises like this 7-day ultramarathon race,
HBV carrier runners may demonstrate more hepatic cell
damage than that of non-HBV carrier runners. Among HBV
carrier runners, baseline liver function should be evaluated and
post-race liver function should be followed closely.
There were some limitations in this study. First, the number
of participants was low. Second, we did not check the titer ofHBV DNA before and after the race, so we were unclear about
the effect of ultramarathons on serum HBV DNA dynamics in
chronic HBV carriers and the relationship to the greater in-
creases of AST, ALT, and T-BIL levels than for non-HBV
carriers. Third, we did not check the liver sonography or
liver fibrosis scan tests for HBV carriers. Globally, the number
of runners that participate in ultramarathons is quite low,
especially races 7 days in duration, so it is quite important to
collect the 7 days' serial change over liver function. Despite
the aforementioned limitations, the main strength of this study
was that we illustrated the serial change between HBV carriers
and non-HBV carriers during a 7-day ultramarathon.
In conclusion, overall, athletes' ALP levels increased and
ALB and TP decreased significantly during a 7-day ultra-
marathon, and then recovered gradually during a 3-day rest
period. Among athletes who were chronic HBV carriers, ALT,
AST, and T-BIL were elevated to significantly higher levels
during the race than in those not infected with the virus. We
suggest that chronically-infected individuals participating in a
7-day ultramarathon should be informed of this phenomenon.
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